<DOC>
	<DOC>NCT01700920</DOC>
	<brief_summary>The purpose of this study is to analyze the safety and feasibility of direct administration intrafemoral mesenchymal stem cells (MSCs) in vitro expanded autologous treatment of patients with femoral osteonecrosis.</brief_summary>
	<brief_title>PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells</brief_title>
	<detailed_description />
	<mesh_term>Osteonecrosis</mesh_term>
	<criteria>Age between 18 and 70 years Clinical diagnosis and imaging (Rx and NMR) of idiopathic osteonecrosis of the femoral head Stadiums &lt;IIIC ARCO ranking Those on investigator judgment not in a good position to tolerate the procedure. Clinical criteria and anesthetics that contraindicate surgery (eg ASA IVV) Serious illness uncontrolled Pregnant women Patients with HIV infection + Acute infection (in the previous 15 days) or chronic (other than HIV) Previous treatments of osteonecrosis Active or previous neoplastic disease (last 5 years) except for patients undergoing allogeneic haematopoietic progenitors who are in complete remission after 2 years after transplantation. Lack of informed consent or revocation thereof.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteonecrosis of the femoral head</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Femoral Head</keyword>
</DOC>